Insights on the Respiratory Inhalers Global Market to 2027 – Featuring AstraZeneca, Cipla and GlaxoSmithKline Among Others –

Insights on the Respiratory Inhalers Global Market to 2027 – Featuring AstraZeneca, Cipla and GlaxoSmithKline Among Others –

Insights on the Respiratory Inhalers Global Market to 2027 – Featuring AstraZeneca, Cipla and GlaxoSmithKline Among Others –

DUBLIN–(BUSINESS WIRE)–The Respiratory Inhalers – Global Market Trajectory & Analytics” report has been added to’s offering.

Amid the COVID-19 crisis, the global market for Respiratory Inhalers estimated at US$33.9 Billion in the year 2020, is projected to reach a revised size of US$51 Billion by 2027, growing at a CAGR of 6% over the period 2020-2027.

Manual, one of the segments analyzed in the report, is projected to grow at a 5.4% CAGR to reach US$45.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Digital segment is readjusted to a revised 13.1% CAGR for the next 7-year period. This segment currently accounts for a 6.9% share of the global Respiratory Inhalers market.

The U.S. Accounts for Over 36.1% of Global Market Size in 2020, While China is Forecast to Grow at a 8.2% CAGR for the Period of 2020-2027

The Respiratory Inhalers market in the U.S. is estimated at US$12.2 Billion in the year 2020. The country currently accounts for a 36.11% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$7 Billion in the year 2027 trailing a CAGR of 8.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 5.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$7 Billion by the year 2027.

Select Competitors (Total 131 Featured) –

  • AstraZeneca plc
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Koninklijke Philips N.V.
  • Merck & Co., Inc
  • Omron Healthcare Europe B.V
  • PARI Medical Holding
  • Teva Pharmaceutical Industries Ltd.

Key Topics Covered:




  • Impact of COVID-19 and a Looming Global Recession
  • 2020 Marked as a Year of Disruption & Transformation
  • Inhalation Technology for Tackling COVID-19
  • Iconovo Joins Hands with ISR to Develop Inhaled Vaccine for COVID-19
  • Ongoing Studies ExploreUse of Inhalers-based Therapies to Treat COVID-19
  • Inhalers Lead to Marked Reduction in Onset of Severe Symptoms for Early COVID-19 Patients
  • Researchers Bet on Corticosteroid Inhalers to Treat COVID-19 Patients
  • Use of Inhalers amid COVID-19 Medical Crisis Outweigh Risks for Asthma Patients
  • COVID-19 Pandemic Pushes Patient Compliance Linked with Inhaler-based Drug Regime
  • Stockpiling Under COVID-19 Shadow Exacerbates Steroid Inhaler Supply Concerns
  • Concerns over COVID-19 Virus Transmission through Nebulizers Paves Way for Broader Acceptance of Respiratory Inhalers
  • Respiratory Inhalers: A Prelude
  • Types of Respiratory Inhalers
  • Metered-dose inhaler
  • Dry Powder Inhaler (DPI)
  • Soft Mist Inhalers (SMI)
  • Nebulizers
  • Pulmonary Drug Delivery using Inhalers Hold Critical Significance to Provide Respite to Patients
  • High Prevalence of Respiratory Diseases to Drive Growth
  • Chronic Disease Type in the US, Germany, and UK
  • Sustained Emphasis on Bringing Novel Pulmonary Disease Treatments Augurs Well for Market Growth
  • Dry Powder Inhalers Set to Drive Gains
  • Digital Dose Inhalers Accelerate Growth Pace
  • Recent Market Activity



  • Rise in Incidence of Asthma Drives Growth Prospects
  • Role of Respiratory Inhalers in Asthma
  • Asthma Rescue Inhalers Medications
  • Asthma Long-Term Medications
  • Select Asthma Stats
  • Rising Prevalence of Asthma in Children Supports Growth
  • Mounting Incidence of COPD Drives Use of Inhalers
  • COPD Stats
  • Acute Respiratory Distress Syndrome: An Emerging Space for Inhalers
  • ARDS Fact Sheet
  • Rising Incidence of Cystic Fibrosis Offers Market Potential
  • Cystic Fibrosis Fact Sheet
  • Combination Therapies Gain Interest as Effective Treatment for Considered Influence Respiratory Inhaler Demand
  • Nebulizer Innovations Drive Opportunities
  • Manufacturers Venture into Nebulizers Designed to Fight COVID-19
  • New Hot Melt Extrusion Method to Enhance Inhaler Technology
  • Advances in Pulmonary Drug Delivery Devices Drive Adoption
  • Select Innovations & Advancements
  • Smart Inhalers Gain Traction
  • Artificial Intelligence to Add Sophistication to Inhaler Technology
  • 3D Printing Seeks Role in Inhaler Manufacturing
  • Rise in Air Pollution Levels and Consequent Increase in Respiratory Diseases Trigger the Demand for Inhalers
  • Inhalers and Pollution: The Irony
  • Ballooning Geriatric Population to Spur Demand
  • Increase in Healthcare Spending Stirs Demand




For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900